ABBV vs LIVN

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

LIVN presents a stark contrast between poor deterministic health and strong market momentum. The Piotroski F-Score of 2/9 indicates significant fundamental weakness, and the technical trend is currently bearish. However, the company maintains strong gross margins (68.01%) and a low debt-to-equity ratio (0.36), while analysts remain bullish with a target price of $79.64. The valuation appears attractive on a PEG basis (0.72), but the negative net profit margin and ROE suggest operational inefficiencies or significant non-operating losses.